tiprankstipranks
Trending News
More News >

Protagenic Therapeutics Announces Reverse Stock Split

Story Highlights
Protagenic Therapeutics Announces Reverse Stock Split

Don’t Miss TipRanks’ Half-Year Sale

An announcement from Protagenic Therapeutics ( (PTIX) ) is now available.

Protagenic Therapeutics announced a 1-for-14 reverse stock split of its common stock, effective May 5, 2025, to comply with Nasdaq’s minimum bid price requirement. This move will reduce the number of outstanding shares significantly, impacting shareholders by consolidating their shares, and is intended to maintain the company’s listing on Nasdaq.

Spark’s Take on PTIX Stock

According to Spark, TipRanks’ AI Analyst, PTIX is a Underperform.

Protagenic Therapeutics faces significant financial difficulties, with no revenue and persistent losses. Technical indicators suggest weak market momentum, and the company’s valuation is unattractive due to negative earnings. These factors collectively result in a low overall stock score, reflecting substantial risks and challenges.

To see Spark’s full report on PTIX stock, click here.

More about Protagenic Therapeutics

Protagenic Therapeutics, Inc. is a biopharmaceutical company focused on developing neuro-active peptides into therapeutics aimed at mitigating stress-related disorders.

YTD Price Performance: -58.08%

Average Trading Volume: 5,372,062

Technical Sentiment Signal: Buy

Current Market Cap: $1.64M

For detailed information about PTIX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1